A Phase 3 interventional study of rVIII-SingleChain in Hemophilia A and Severe Hemophilia A, sponsored by CSL Behring. Completed at 64 sites in 25 countries. Open to male participants. Per ClinicalTrials.gov, last updated 2021-10-27.
Sponsored by CSL Behring (part of CSL Limited) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Hemophilia A by CSL Limited — none open to participants now, none under way, none of them phase 3. Hemophilia A · CSL Limited.
Among the 14 studies in Hemophilia A by CSL Limited, this one has the largest enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2014, is one of 6 in phase 3, and was the 9th registered.
844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.
Browse Hemophilia A studies →None of the 14 studies in Hemophilia A by CSL Limited is open now. The open studies under Hemophilia A, anywhere →
Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.
This study: male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 8 · Phase 4 1
First in 2001; this study’s year is marked. 2 started in 2014.
This study's enrollment of 246 is above the median of 30 across 499 interventional studies indexed under Hemophilia A.
Median enrollment 62 across the 11 interventional studies, 62 across the 3 observational. Of the 14 that completed or were terminated, 5 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under CSL Behring, one of the names counted as CSL Limited. Under that name alone:
CSL Behring is the lead sponsor of 145 studies on the registry; 17 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 17 (71%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Hemophilia A by CSL Limited, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This multicenter, open-label, phase 3 extension study will investigate the safety and efficacy of rVIII-SingleChain for prophylaxis and on-demand treatment of bleeding episodes in at least 200 previously treated patients (PTPs) with severe congenital hemophilia A and previous exposure to FVIII products who achieve at least 100 exposure days (EDs) to rVIII-SingleChain in this study, as well as in previously untreated patients (PUPs) with no previous exposure to any FVIII product who achieve at least 50 EDs to rVIII-SingleChain in this study. A substudy (open to both PTPs and PUPs) will investigate the use of rVIII-SingleChain in surgery. A substudy (open to PUPs who develop an inhibitor to rVIII-SingleChain) will investigate the use of rVIII-SingleChain in immune tolerance induction (ITI) therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
PTPs:
PUPs:
ITI substudy:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The investigator will assign subjects to either prophylaxis or on-demand treatment regimens for rVIII-SingleChain by intravenous injection. The investigator will determine the rVIII-SingleChain dose and dosing schedule for the subject based upon the subject's pharmacokinetic (PK) profile, rVIII-SingleChain PK data, previous FVIII treatment regimen, and bleeding phenotype, if available.
Biological: rVIII-SingleChain
The investigator will assign subjects to either prophylaxis or on-demand treatment regimens for rVIII-SingleChain by intravenous injection. The investigator will determine the rVIII-SingleChain dose and dosing schedule at their discretion, taking into consideration the World Federation of Hemophilia (WFH) guidelines, the type of bleeding episode, location of the bleeding, subject's age, and other disease characteristics.
Biological: rVIII-SingleChain
Recombinant single-chain coagulation factor VIII
Also known as: CSL627
Incidence of Inhibitor Formation to FVIII in Previously Treated Patients (PTPs) With 100 Exposure Days (EDs) to CSL627
Time frame: At the closest visit after 100 EDs (up to 5 years).
Number of Previously Untreated Patients (PUPs) With High-titer Inhibitor Formation to FVIII With at Least 50 EDs to CSL627
High-titer inhibitor is defined as an inhibitor titer of ≥ 5 Bethesda units/mL.
Time frame: At the closest visit after 50 EDs (up to 5 years).
Percent Treatment Success for Major Bleeding Episodes in PUPs
Percentage of major bleeding episodes treated successfully where treatment success for a bleeding episode is defined as a rating of "excellent" or "good" on the investigator's clinical assessment of hemostatic efficacy 4-point scale "excellent, good, moderate or poor/no response". Major bleeding episodes are defined as bleeding episodes for which a subject is required to seek treatment at the hemophilia center or that threatens the subject's life or loss of limb.
Time frame: Up to 5 years
Annualized Spontaneous Bleeding Rate in PUPs
The annualized spontaneous bleeding rate for PUPs taking prophylaxis and on-demand treatment regimens.
Time frame: Up to 5 years
Percentage of Bleeding Episodes Treated Successfully in PTPs
Percentage of bleeding episodes treated successfully where treatment success for a bleeding episode is defined as a rating of "excellent" or "good" on the investigator's clinical assessment of hemostatic efficacy 4-point scale "excellent, good, moderate or poor/no response".
Time frame: Up to 5 years
Annualized Bleeding Rate in PTPs and PUPs
The annualized bleeding rate for PTPs and PUPs taking prophylaxis and on-demand treatment regimens
Time frame: Up to 5 years
Percentage of Bleeding Episodes Requiring 1, 2, 3, or > 3 Injections of CSL627 to Achieve Hemostasis in PTPs and PUPs
Time frame: Up to 5 years
Mean Number of On-demand Infusions of CSL627
Time frame: Up to 5 years
Mean On-demand Dose Administered of CSL627
Time frame: Up to 5 years
Mean Prophylaxis Dose Administered of CSL627
Time frame: Up to 5 years
Mean Total Amount of CSL627 Administered During Surgery Period in PTPs
Time frame: Day of surgery up to 336 hours post-surgery
Total Amount of CSL627 Administered During Surgery Period in PUPs
Time frame: Day of surgery up to 336 hours post-surgery
Hemostatic Efficacy of rVIII-SingleChain for PTPs and PUPs Who Undergo Surgery
The investigator will rate the efficacy of the rVIII-SingleChain treatment during surgery based on a hemostatic efficacy four point rating scale of "excellent, good, moderate or poor/no response".
Time frame: From the start of surgery through the post-operative recovery (generally up to 14 days after surgery)
Incidence of Inhibitor Formation to FVIII in PTPs After 10 EDs and After 50 EDs
Time frame: Up to 5 years
Percentage of PTPs and PUPs Developing Antibodies Against CSL627
Time frame: PTPs: At the closest visit after 100 EDs (up to 5 years). PUPs: At the closest visit after 50 EDs (up to 5 years).
Percentage of PTPs and PUPs Developing Antibodies to Chinese Hamster Ovary (CHO) Proteins
Time frame: PTPs: At the closest visit after 100 EDs (up to 5 years). PUPs: At the closest visit after 50 EDs (up to 5 years).
Number of PUPs With High-titer Inhibitor Formation to FVIII After 10 EDs With CSL627
High-titer inhibitor is defined as an inhibitor titer of ≥ 5 Bethesda units/mL.
Time frame: At the closest visit after 10 EDs (up to 5 years)
Number of PUPs With Low-titer Inhibitor Formation to FVIII After 10 EDs and After 50 EDs With CSL627
Low-titer inhibitor is defined as an inhibitor titer of less than 5 Bethesda units/mL.
Time frame: At the closest visit after 10 and after 50 EDs (up to 5 years)
Incidence of Total Inhibitor Formation to FVIII in PUPs
Time frame: Up to 5 years
Percent Treatment Success for Non-major Bleeding Episodes in PUPs
Percentage of bleeding episodes treated successfully where treatment success for a bleeding episode is defined as a rating of "excellent" or "good" on the investigator's clinical assessment of hemostatic efficacy 4-point scale "excellent, good, moderate or poor/no response". Non-major bleeding episodes are those not requiring treatment at the hemophilia center or not threatening subject's life or loss of limb.
Time frame: Up to 5 years
Percentage of PUPs With Clinically Significant Abnormal Vital Signs Values After First Infusion of CSL627
Vital signs assessments include heart rate, blood pressure, and body temperature. Clinical significance of an abnormality will be assessed by the investigator.
Time frame: Up to 6 hours after first infusion
Percentage of PUPs With Treatment-emergent Clinically Significant Abnormal Vital Signs Values
Vital signs assessments include heart rate, blood pressure, and body temperature. Clinical significance of an abnormality will be assessed by the investigator.
Time frame: Up to 5 years
| Milestone | Previously Treated Patients (PTPs) | Previously Untreated Patients (PUPs) |
|---|---|---|
| Started | 222 | 24 |
| Completed | 197 | 19 |
| Not completed | 25 | 5 |
| Withdrew: Physician decision | 3 | 3 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Withdrew: Adverse event | 4 | 1 |
| Withdrew: Withdrawal by subject | 10 | 0 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Patient traveling | 1 | 0 |
| Withdrew: Patient went to other country | 1 | 0 |
| Withdrew: Patient relocated overseas | 1 | 1 |
| Withdrew: Patient moving | 1 | 0 |
| percentage of paticipants | CSL627: Previously Treated Patients (PTPs) |
|---|---|
| Incidence of Inhibitor Formation to FVIII in Previously Treated Patients (PTPs) With 100 Exposure Days (EDs) to CSL627 | 0 |
High-titer inhibitor is defined as an inhibitor titer of ≥ 5 Bethesda units/mL.
| participants | CSL627: Previously Untreated Patients (PUPs) |
|---|---|
| Number of Previously Untreated Patients (PUPs) With High-titer Inhibitor Formation to FVIII With at Least 50 EDs to CSL627 | 5 |
Percentage of major bleeding episodes treated successfully where treatment success for a bleeding episode is defined as a rating of "excellent" or "good" on the investigator's clinical assessment of hemostatic efficacy 4-point scale "excellent, good, moderate or poor/no response". Major bleeding episodes are defined as bleeding episodes for which a subject is required to seek treatment at the hemophilia center or that threatens the subject's life or loss of limb.
| percentage of treatment success | CSL627: Previously Untreated Patients (PUPs) |
|---|---|
| Percent Treatment Success for Major Bleeding Episodes in PUPs | 100 |
The annualized spontaneous bleeding rate for PUPs taking prophylaxis and on-demand treatment regimens.
| Number of Spontaneous bleeds per year | CSL627: Previously Untreated Patients (PUPs) |
|---|---|
| On-demand | 1.9 ± 2.252 |
| Prophylaxis | 4.04 ± 6.374 |
Percentage of bleeding episodes treated successfully where treatment success for a bleeding episode is defined as a rating of "excellent" or "good" on the investigator's clinical assessment of hemostatic efficacy 4-point scale "excellent, good, moderate or poor/no response".
| Percentage of treated bleeding events | CSL627: Previously Treated Patients (PTPs) |
|---|---|
| Percentage of Bleeding Episodes Treated Successfully in PTPs | 87.1 (75.3 to 93.7) |
The annualized bleeding rate for PTPs and PUPs taking prophylaxis and on-demand treatment regimens
| Number of bleeds per year | CSL627: Previously Treated Patients (PTPs) | CSL627: Previously Untreated Patients (PUPs) |
|---|---|---|
| On-demand | 28.32 ± 29.014 | 5.12 ± 5.331 |
| Prophylaxis | 2.84 ± 4.981 | 5.94 ± 7.705 |
| Percentage of treated bleeds | CSL627: Previously Treated Patients (PTPs) | CSL627: Previously Untreated Patients (PUPs) |
|---|---|---|
| 1 infusion | 71.5 | 77.5 |
| 2 infusions | 14.8 | 11.4 |
| 3 infusions | 6.9 | 5.4 |
| >3 infusions | 6.3 | 3.5 |
| Number of infusions | CSL627: Previously Treated Patients (PTPs) | CSL627: Previously Untreated Patients (PUPs) |
|---|---|---|
| per participant per month | 6.26 ± 4.778 | 1.23 ± 1.296 |
| per participant per year | 75.18 ± 57.335 | 14.75 ± 15.547 |
| IU/kg | CSL627: Previously Treated Patients (PTPs) | CSL627: Previously Untreated Patients (PUPs) |
|---|---|---|
| per participant per month | 210.39 ± 188.106 | 41.93 ± 44.643 |
| per participant per year | 2524.69 ± 2257.278 | 503.16 ± 535.712 |
| IU/kg | CSL627: Previously Treated Patients (PTPs) | CSL627: Previously Untreated Patients (PUPs) |
|---|---|---|
| per participant per month | 380.95 ± 130.079 | 389.30 ± 243.191 |
| per participant per year | 4571.35 ± 1560.944 | 4671.54 ± 2918.288 |
| IU | CSL627: Previously Treated Patients (PTPs) |
|---|---|
| Mean Total Amount of CSL627 Administered During Surgery Period in PTPs | 51663.0 ± 62033.25 |
| IU | CSL627: Previously Untreated Patients (PUPs) |
|---|---|
| Participant 1 | 15693 |
| Participant 2 | 5631 |
| Participant 3 | 7330 |
The investigator will rate the efficacy of the rVIII-SingleChain treatment during surgery based on a hemostatic efficacy four point rating scale of "excellent, good, moderate or poor/no response".
| Number of surgeries | CSL627: Previously Treated Patients (PTPs) | CSL627: Previously Untreated Patients (PUPs) |
|---|---|---|
| Excellent | 28 | 3 |
| Good | 4 | 0 |
| Moderate | 0 | 0 |
| Poor/No response | 0 | 0 |
| percentage of participants | CSL627: Previously Treated Patients (PTPs) |
|---|---|
| after 10 EDs | 0 |
| after 50 EDs | 0 |
| percentage of participants | CSL627: Previously Treated Patients (PTPs) | CSL627: Previously Untreated Patients (PUPs) |
|---|---|---|
| Percentage of PTPs and PUPs Developing Antibodies Against CSL627 | 15.3 | 70.8 |
| percentage of participants | CSL627: Previously Treated Patients (PTPs) | CSL627: Previously Untreated Patients (PUPs) |
|---|---|---|
| Percentage of PTPs and PUPs Developing Antibodies to Chinese Hamster Ovary (CHO) Proteins | 0 | 0 |
High-titer inhibitor is defined as an inhibitor titer of ≥ 5 Bethesda units/mL.
| participants | CSL627: Previously Untreated Patients (PUPs) |
|---|---|
| Number of PUPs With High-titer Inhibitor Formation to FVIII After 10 EDs With CSL627 | 4 |
Low-titer inhibitor is defined as an inhibitor titer of less than 5 Bethesda units/mL.
| participants | CSL627: Previously Untreated Patients (PUPs) |
|---|---|
| after 10 EDs | 4 |
| after 50 EDs | 0 |
| percentage of participants | CSL627: Previously Untreated Patients (PUPs) |
|---|---|
| Incidence of Total Inhibitor Formation to FVIII in PUPs | 50.0 |
Percentage of bleeding episodes treated successfully where treatment success for a bleeding episode is defined as a rating of "excellent" or "good" on the investigator's clinical assessment of hemostatic efficacy 4-point scale "excellent, good, moderate or poor/no response". Non-major bleeding episodes are those not requiring treatment at the hemophilia center or not threatening subject's life or loss of limb.
| percentage of treated bleeding events | CSL627: Previously Untreated Patients (PUPs) |
|---|---|
| Percent Treatment Success for Non-major Bleeding Episodes in PUPs | 92.1 (87.0 to 95.3) |
Vital signs assessments include heart rate, blood pressure, and body temperature. Clinical significance of an abnormality will be assessed by the investigator.
| percentage of participants | CSL627: Previously Untreated Patients (PUPs) |
|---|---|
| Percentage of PUPs With Clinically Significant Abnormal Vital Signs Values After First Infusion of CSL627 | 0 |
Vital signs assessments include heart rate, blood pressure, and body temperature. Clinical significance of an abnormality will be assessed by the investigator.
| percentage of participants | CSL627: Previously Untreated Patients (PUPs) |
|---|---|
| Percentage of PUPs With Treatment-emergent Clinically Significant Abnormal Vital Signs Values | 0 |
Collected over Up to 5 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CSL627: Previously Treated Patients (PTPs) | 1/222 (0.5%) | 23/222 (10.4%) | 130/222 (58.6%) |
| CSL627: Previously Untreated Patients (PUPs) | 0/24 (0%) | 14/24 (58.3%) | 23/24 (95.8%) |
| Event | CSL627: Previously Treated Patients (PTPs) | CSL627: Previously Untreated Patients (PUPs) |
|---|---|---|
| Anti factor VIII antibody positiveInvestigations | 0/222 | 6/24 |
| Inhibiting antibodies positiveInvestigations | 0/222 | 5/24 |
| FallInjury, poisoning and procedural complications | 0/222 | 2/24 |
| HaemorrhageVascular disorders | 0/222 | 1/24 |
| Wound haemorrhageInjury, poisoning and procedural complications | 0/222 | 1/24 |
| Factor VIII inhibitionBlood and lymphatic system disorders | 0/222 | 1/24 |
| Mouth haemorrhageGastrointestinal disorders | 0/222 | 1/24 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 0/222 | 1/24 |
| Device related infectionInfections and infestations | 0/222 | 1/24 |
| Acinetobacter infectionInfections and infestations | 0/222 | 1/24 |
| Event | CSL627: Previously Treated Patients (PTPs) | CSL627: Previously Untreated Patients (PUPs) |
|---|---|---|
| PyrexiaGeneral disorders | 14/222 | 15/24 |
| NasopharyngitisInfections and infestations | 40/222 | 9/24 |
| Upper respiratory tract infectionInfections and infestations | 25/222 | 7/24 |
| CoughRespiratory, thoracic and mediastinal disorders | 13/222 | 6/24 |
| RhinitisInfections and infestations | 7/222 | 6/24 |
| VaricellaInfections and infestations | 2/222 | 6/24 |
| DiarrhoeaGastrointestinal disorders | 5/222 | 5/24 |
| TonsillitisInfections and infestations | 13/222 | 5/24 |
| Ear infectionInfections and infestations | 5/222 | 5/24 |
| InfluenzaInfections and infestations | 14/222 | 4/24 |
Age was analyzed separately as PTPs and PUPs
| Age, Categorical(Participants) | Previously Treated Patients (PTPs) | Previously Untreated Patients (PUPs) | Total |
|---|---|---|---|
| <=18 years | 95 | 24 | 119 |
| Between 18 and 65 years | 126 | 0 | 126 |
| >=65 years | 1 | 0 | 1 |
| Age, Continuous(years) | Previously Treated Patients (PTPs) | Previously Untreated Patients (PUPs) | Total |
|---|---|---|---|
| PTPs | 22.5 ± 14.55 | — | 22.5 ± 14.55 |
| PUPs | — | 1.4 ± 1.18 | 1.4 ± 1.18 |
| Sex: Female, Male(Participants) | Previously Treated Patients (PTPs) | Previously Untreated Patients (PUPs) | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 222 | 24 | 246 |
| Ethnicity (NIH/OMB)(Participants) | Previously Treated Patients (PTPs) | Previously Untreated Patients (PUPs) | Total |
|---|---|---|---|
| Hispanic or Latino | 10 | 1 | 11 |
| Not Hispanic or Latino | 212 | 23 | 235 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Previously Treated Patients (PTPs) | Previously Untreated Patients (PUPs) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 50 | 2 | 52 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 12 | 7 | 19 |
| White | 158 | 15 | 173 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 0 | 2 |
| Region of Enrollment(participants) | Previously Treated Patients (PTPs) | Previously Untreated Patients (PUPs) | Total |
|---|---|---|---|
| Czechia | 2 | 0 | 2 |
| United States | 21 | 1 | 22 |
| Malaysia | 13 | 2 | 15 |
| Thailand | 10 | 0 | 10 |
| Portugal | 2 | 3 | 5 |
| Austria | 6 | 0 | 6 |
| Netherlands | 9 | 3 | 12 |
| Ireland | 5 | 0 | 5 |
| Poland | 36 | 0 | 36 |
| France | 7 | 0 | 7 |
| Romania | 4 | 0 | 4 |
| Hungary | 2 | 0 | 2 |
| Japan | 7 | 0 | 7 |
| Philippines | 18 | 0 | 18 |
| Ukraine | 17 | 0 | 17 |
| United Kingdom | 1 | 0 | 1 |
| Switzerland | 1 | 0 | 1 |
| Spain | 6 | 0 | 6 |
| Lebanon | 9 | 3 | 12 |
| Canada | 1 | 0 | 1 |
| Italy | 5 | 4 | 9 |
| South Africa | 14 | 8 | 22 |
| Georgia | 5 | 0 | 5 |
| Australia | 11 | 0 | 11 |
| Germany | 10 | 0 | 10 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Oct 2014, a primary completion of Jan 2021 and a completion of Jan 2021. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2021, 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lonoctocog alfa